RT Journal Article SR Electronic T1 Prevalence and Incidence of Antibodies Against Sars-Cov-2 Among Primary Healthcare Providers in Belgium During One Year of the Covid-19 Epidemic: Prospective Cohort Study Protocol JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.18.21259139 DO 10.1101/2021.06.18.21259139 A1 Adriaenssens, Niels A1 Scholtes, Beatrice A1 Bruyndonckx, Robin A1 Verbakel, Jan Y A1 De Sutter, An A1 Heytens, Stefan A1 Van den Bruel, Ann A1 Desombere, Isabelle A1 Van Damme, Pierre A1 Goossens, Herman A1 Buret, Laëtitia A1 Duysburgh, Els A1 Coenen, Samuel YR 2021 UL http://medrxiv.org/content/early/2021/06/23/2021.06.18.21259139.abstract AB Introduction National severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence data provides essential information about population exposure to the virus and helps predict the future course of the epidemic. Early cohort studies have suggested declines in levels of antibodies in individuals, associated with, for example, illness severity, age and co-morbidities. This protocol focuses on the seroprevalence among primary health care providers (PHCPs) in Belgium. They manage the vast majority of COVID-19 patients in addition to other patients and therefore play an essential role in the efficient organisation of health care. Currently, evidence is lacking on 1. how many PHCPs get infected with SARS-CoV-2 in Belgium, 2. the rate at which this happens, 3. their clinical spectrum, 4. their risk factors, 5. the effectiveness of the measures to prevent infection and 6. the accuracy of the serology-based point-of-care test in a primary care setting.Methods and analysis This study will be set up as a prospective cohort study. General practitioners (GPs) and other PHCPs (working in a GP practice) will be recruited via professional networks and professional media outlets to register online to participate. Registered GPs and other PHCPs will be asked at each testing point (n=9) to perform a capillary blood sample antibody point-of-care test (OrientGene®) and complete an online questionnaire. The primary outcomes are the prevalence and incidence of antibodies against SARS-CoV-2 in PHCPs during a 12-month follow-up period. Secondary outcomes include the longevity of antibodies against SARS-CoV-2.Ethics and dissemination Ethical approval has been granted by the Ethics Committee of the University Hospital Antwerp/University of Antwerp (Belgian registration number: 3002020000237). Alongside journal publications, dissemination activities include the publication of monthly reports to be shared with the participants and the general population through the publicly available website of the Belgian health authorities (Sciensano).Registration Trial registration number: NCT04779424Strengths and limitations of this studyThis large cohort study will provide regular, timely and precise data at national level on prevalence and incidence of antibodies against SARS-CoV-2 among primary health care providers (PHCPs) managing the vast majority of COVID-19 and other patients and therefore essential to organise health care efficiently.This study will familiarise PHCPs with the use of serology-based point-of-care tests (POCTs) and validate the POCT in a primary care setting.Missing data points and the use of a convenience sample could limit the validity of the study results.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04779424Funding StatementThis work was supported by Sciensano, grant number [OZ8478]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval has been granted by the Ethics Committee of the University Hospital Antwerp/University of Antwerp (Belgian registration number: 3002020000237).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. Requests can be directed at both samuel.coenen{at}uantwerpen.be and elza.duysburgh{at}sciensano.be. https://datastudio.google.com/embed/reporting/7e11980c-3350-4ee3-8291-3065cc4e90c2/page/ZwmOB.